2Magnus T, Beck M, Giess R, et al. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve ,2002,25:709-714.
3Kimura F, Fujimura C, Ishida S , et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology, 2006,66 : 265 -267.
4Kaufmann P, Levy G, Thompson JL, et al. The ALSFRSr predicts survival time in an ALS clinic population. Neurology, 2005,64 : 38-43.
5Miller RG, Moore DH 2 nd, Gelinas DF, et al. Phase Ⅲ randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology,2001,56:843-848.
6Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. A randomized, placebo-controlled trial of topiamate in amyotrophic lateral sclerosis. Neurology, 2003,61:456-464.
7Yuen E, Olney R. Longitudinal study of fibre density and motor unit estimates in patients with amytrophic lateral sclerosis. Neurology, 1997,49:573-578.
8Cedarbaum JM, Stambler N, Malta E , et al. The ALSFRS-R : a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group ( phase Ⅲ ). J Neurol Sci, 1999,169 : 13-21.
9Traynor B J, Zhang H, Shefner JM , et al. Functional outcome measures as clinical trial endpoints in ALS. Neurology,2004,63: 1933-1935.
10Brooks BR, Miller RG, Swash M , et al. E1 Escorial revisited : revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord ,2000,1:293- 299.
5D'Andrea I. Early social enrichment by communal nest increases resilience to depression-like in female than in male mice [J]. Behav Res, 2010,215( 1 ) :71-76.
